Search

Your search keyword '"Ferrari, Francesca"' showing total 529 results

Search Constraints

Start Over You searched for: Author "Ferrari, Francesca" Remove constraint Author: "Ferrari, Francesca" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
529 results on '"Ferrari, Francesca"'

Search Results

3. Describing the Process and Tools Adopted to Cocreate a Smartphone App for Obesity Prevention in Childhood: Mixed Method Study

8. 3-Manifolds and VOA Characters

10. Supergroups, q-series and 3-manifolds

11. Three-Manifold Quantum Invariants and Mock Theta Functions

16. 3d Modularity

18. Properties of extremal CFTs with small central charge

19. Smart IoT system empowered by customized energy-aware wireless sensors integrated in graphene-based tissues to improve workers thermal comfort

22. Mixed Rademacher and BPS Black Holes

26. Landau-Ginzburg Orbifolds and Symmetries of K3 CFTs

31. Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity

37. Haunted Bauhaus: Occult Spirituality, Gender Fluidity, Queer Identities, and Radical Politics

43. Data from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

44. Supplementary Figure S1 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

45. Data from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

46. Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

47. Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

48. Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

50. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro

Catalog

Books, media, physical & digital resources